Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia in Adults

NCT06034561 is registered in ClinicalTrials.gov with Instituto do Cancer do Estado de São Paulo as lead sponsor.

NCT NCT06034561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06034561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia in Adults
Lead sponsor
Instituto do Cancer do Estado de São Paulo
Phase
Phase 2
Overall status
Recruiting
Start date
April 1, 2024
Completion date
August 31, 2029
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia with failed remission, acute lymphoblastic leukemia, in relapse